Funding – Talk Bio

Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns

1 month ago talkbio0Tagged Acquired Immunodeficiency Syndrome, Administration occupational activities, Advocacy, Centers for Disease Control and Prevention (U.S.), Funding, HIV Prevention, public health medicine (field), Transplant Registry Unified Management Program

HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

2 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years

3 months ago talkbio0Tagged Altman, Artificial (qualifier value), Biosciences, Biotechnology, Dorsal, Funding, Health care facility, Homo sapiens, Intelligence, Lifespan Extension, Series

Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare

Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

3 months ago talkbio0Tagged Cancer Therapeutic Procedure, Funding, genetic editing, Light Horse, Novartis, Precision - temporal, Series, small molecule therapeutics

Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform

Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery

4 months ago talkbio0Tagged biologic drug alternatives, Funding, nCycles, Oral Macrocycle, Orbis Medicines, pharmaceutical innovation, Series

Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation

Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker

4 months ago talkbio0Tagged biotech, Biotech Fundraising Tracker, Biotech Investments, Capital, Fierce, Funding, funding rounds, Orbis, Series, venture

Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds

CDC Faces Uncertainty Amid Leadership Change and Funding Threats

5 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Dr. Mandy, Funding, health threats, Leadership Change, public health medicine (field), threat

CDC, leadership change, funding threats, public health, emerging health threats, Dave Weldon, Dr. Mandy Cohen

Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations

5 months ago talkbio0Tagged Drug Development, Funding, Generative Protein Design, Multipass Membrane, Pharmaceutical Collaborations, Proteins, Series, Therapeutic Antibodies

Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding

Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases

7 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Arda, Eli, Eli Lilly, fibrotic diseases, Funding, Horowitz, Immunostimulating conjugate (antigen), Series

Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)